Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20138191 | 0.92 | PDE4B (0.37) | PARP1TRPV1CDK7CDK9SMYD3 | |
| SCHEMBL20138247 | 0.86 | TRPV1 (0.35) | PARP1TRPV1CDK7CDK9 | |
| SCHEMBL28525837 | 0.86 | MAPT (0.45) | — | |
| SCHEMBL18305086 | 0.81 | NR3C1 (0.37) | PARP1TRPV1NPC1RAB9AATM | |
| SCHEMBL20137956 | 0.77 | HTR2A (0.34) | PARP1TRPV1 | |
| Hydrochloric Acid SCHEMBL20137965 | 0.77 | PARP1 (0.33) | PARP1TRPV1 | |
| SCHEMBL18305073 | 0.73 | NR3C1 (0.39) | TRPV1 | |
| SCHEMBL18128160 | 0.71 | POLB (0.42) | PARP1TRPV1SMYD3 | |
| SCHEMBL30806796 | 0.69 | PARP1 (0.44) | PARP1SMYD3 | |
| SCHEMBL28525830 | 0.69 | KDM4E (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | PARP1 1553/4885TRPV1 92/4885CDK7 3776/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | PARP1 2142/4885TRPV1 203/4885CDK7 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.